| abstract |
Compounds of formula (I) (Wherein R 1 , R 6 , R 8 , Q 2 , Q 3 , Q 3a , Q 4 , L and A have the meanings defined in the specification) and pharmaceutically acceptable salts thereof Thus, compounds are provided that are useful in the treatment of diseases where inhibition of the activity of members of the MAPEG family is desired and / or required, particularly in the treatment of inflammation and / or cancer. |